Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.08
AUXL's Cash to Debt is ranked lower than
54% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. AUXL: 0.08 )
AUXL' s 10-Year Cash to Debt Range
Min: 0.08   Max: 15218
Current: 0.08

0.08
15218
Equity to Asset 0.16
AUXL's Equity to Asset is ranked lower than
54% of the 754 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AUXL: 0.16 )
AUXL' s 10-Year Equity to Asset Range
Min: -2.27   Max: 0.68
Current: 0.16

-2.27
0.68
F-Score: 1
Z-Score: 0.46
M-Score: -3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -26.59
AUXL's Operating margin (%) is ranked higher than
53% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.92 vs. AUXL: -26.59 )
AUXL' s 10-Year Operating margin (%) Range
Min: -335.41   Max: 21.62
Current: -26.59

-335.41
21.62
Net-margin (%) -39.32
AUXL's Net-margin (%) is ranked higher than
52% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. AUXL: -39.32 )
AUXL' s 10-Year Net-margin (%) Range
Min: -327.31   Max: 21.74
Current: -39.32

-327.31
21.74
ROE (%) -64.77
AUXL's ROE (%) is ranked lower than
51% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.33 vs. AUXL: -64.77 )
AUXL' s 10-Year ROE (%) Range
Min: -111.79   Max: 60.46
Current: -64.77

-111.79
60.46
ROA (%) -13.92
AUXL's ROA (%) is ranked higher than
54% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. AUXL: -13.92 )
AUXL' s 10-Year ROA (%) Range
Min: -1000.92   Max: 27.33
Current: -13.92

-1000.92
27.33
ROC (Joel Greenblatt) (%) -298.47
AUXL's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.20 vs. AUXL: -298.47 )
AUXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2174.84   Max: 290.53
Current: -298.47

-2174.84
290.53
Revenue Growth (%) 22.10
AUXL's Revenue Growth (%) is ranked higher than
86% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AUXL: 22.10 )
AUXL' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 28.7
Current: 22.1

0
28.7
EBITDA Growth (%) -36.80
AUXL's EBITDA Growth (%) is ranked higher than
50% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AUXL: -36.80 )
AUXL' s 10-Year EBITDA Growth (%) Range
Min: -68.8   Max: 75
Current: -36.8

-68.8
75
EPS Growth (%) -30.00
AUXL's EPS Growth (%) is ranked higher than
56% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. AUXL: -30.00 )
AUXL' s 10-Year EPS Growth (%) Range
Min: -70.7   Max: 81.6
Current: -30

-70.7
81.6
» AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AUXL Guru Trades in Q3 2013

Steven Cohen 1,136,631 sh (+40.91%)
Paul Tudor Jones 39,500 sh (-11.24%)
Jim Simons 238,500 sh (-74.31%)
» More
Q4 2013

AUXL Guru Trades in Q4 2013

Paul Tudor Jones 32,000 sh (-18.99%)
Jim Simons 115,900 sh (-51.4%)
Steven Cohen 423,581 sh (-62.73%)
» More
Q1 2014

AUXL Guru Trades in Q1 2014

John Paulson 4,000,000 sh (New)
Jim Simons 125,895 sh (+8.62%)
Paul Tudor Jones 10,900 sh (-65.94%)
Steven Cohen 36,463 sh (-91.39%)
» More
Q2 2014

AUXL Guru Trades in Q2 2014

Louis Moore Bacon 150,000 sh (New)
John Paulson 4,000,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-03-31 New Buy0.53%$19.99 - $32.005 $ 30.0414%4000000
George Soros 2011-12-31 Sold Out 0.06%$14.21 - $19.93 $ 30.0480%0
George Soros 2011-09-30 New Buy0.06%$13.95 - $20.84 $ 30.0475%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.41
AUXL's P/B is ranked higher than
54% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. AUXL: 8.41 )
AUXL' s 10-Year P/B Range
Min: 1.85   Max: 67.57
Current: 8.41

1.85
67.57
P/S 3.68
AUXL's P/S is ranked higher than
71% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. AUXL: 3.68 )
AUXL' s 10-Year P/S Range
Min: 0.45   Max: 15.15
Current: 3.68

0.45
15.15
EV-to-EBIT -18.93
AUXL's EV-to-EBIT is ranked higher than
55% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.17 vs. AUXL: -18.93 )
AUXL' s 10-Year EV-to-EBIT Range
Min: 3.2   Max: 38.5
Current: -18.93

3.2
38.5
Current Ratio 0.99
AUXL's Current Ratio is ranked lower than
51% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. AUXL: 0.99 )
AUXL' s 10-Year Current Ratio Range
Min: 0.99   Max: 5.85
Current: 0.99

0.99
5.85
Quick Ratio 0.71
AUXL's Quick Ratio is ranked lower than
51% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. AUXL: 0.71 )
AUXL' s 10-Year Quick Ratio Range
Min: 0.71   Max: 5.59
Current: 0.71

0.71
5.59

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.85
AUXL's Price/Median PS Value is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.27 vs. AUXL: 0.85 )
AUXL' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.81
Current: 0.85

0.15
2.81
Earnings Yield (Greenblatt) 2.80
AUXL's Earnings Yield (Greenblatt) is ranked higher than
63% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. AUXL: 2.80 )
AUXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 30.9
Current: 2.8

2.6
30.9
Forward Rate of Return (Yacktman) -0.43
AUXL's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. AUXL: -0.43 )
AUXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -1.2
Current: -0.43

-1.8
-1.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FEJ.Germany
Auxilium Pharmaceuticals, Inc. incorporated in the state of Delaware. The company is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. It is currently market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). Testim is a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, and adverse changes in body composition, irritability and poor concentration. XIAFLEX is a proprietary, injectable collagenase enzyme approved by the United States ('U.S') Food and Drug Administration ('FDA') for the treatment of Dupuytren's contracture ('Dupuytren's') in adult patients with a palpable cord. Its current product pipeline includes: Phase III- XIAFLEX for the treatment of Peyronie's with top-line data expected late in the second quarter of 2012; Phase IIa: XIAFLEX for the treatment of Adhesive Capsulitis ('Frozen Shoulder syndrome') with top-line data expected in the first half of 2013; Phase Ib: XIAFLEX for the treatment of edematous fibrosclerotic panniculopathy ('cellulite') with top-line data expected in the fourth quarter of 2012. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors and chain drug stores who generally sell products to retail pharmacies, hospitals and other institutional customers. It is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws, false claims laws and physician self-referral laws.
» More Articles for AUXL

Headlines

Articles On GuruFocus.com
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 08 2009 


More From Other Websites
Auxilium Pharma (AUXL) Upgraded From Sell to Hold Sep 29 2014
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA Sep 24 2014
Auxilium Pharma downgraded by RBC Capital Mkts Sep 24 2014
Moody's says may review M&As if new tax rules lead to altered terms Sep 23 2014
Auxilium Pharmaceuticals Favors QLT Deal Over Endo Bid Sep 23 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 22 2014
Auxilium Says Endo Takeover Offer Undervalues Company Sep 22 2014
Auxilium says Endo offer undervalues company, but open to talks Sep 22 2014
[$$] Auxilium Sticks With QLT's Merger Deal Sep 22 2014
Endo: Buyout offer for Auxilium 'compelling,' provides 'substantial premium' Sep 22 2014
Endo International Comments On Auxilium Pharmaceutical's Rejection Of Its Acquisition Proposal Sep 22 2014
Auxilium’s Board Rejects Takeover Approach From Endo Sep 22 2014
Auxilium Pharma rejects Endo's takeover offer Sep 22 2014
Auxilium Pharma rejects Endo's takeover offer Sep 22 2014
Auxilium says Endo's offer "significantly undervalues" company Sep 22 2014
Auxilium favors merger agreement with QLT over Endo bid Sep 22 2014
Auxilium favors merger agreement with QLT over Endo bid Sep 22 2014
Auxilium Provides Transaction Update Sep 22 2014
VIVUS and Auxilium Announce Stendra Label Expansion Sep 19 2014
FDA OKs faster-acting label for ED drug Stendra Sep 18 2014
[$$] Stendra Gets FDA Approval as 'On-Demand' Drug Sep 18 2014
How Will Auxilium Pharmaceuticals (AUXL) Stock React to FDA's Stendra Approval? Sep 18 2014
Auxilium Pharmaceuticals' Slow Response to Endo Troubles Investors Sep 18 2014
Endo offers to buy Auxilium Pharma for about $2.2 billion Sep 16 2014
Endo Int'l makes $1.4B offer for Auxilium Pharma Sep 16 2014
Auxilium Pharma says will cut workforce 30 percent Sep 09 2014
Auxilium to combine with eye drug maker QLT Jun 26 2014
BUZZ-U.S. Stocks on the Move-GoPro, Bank stocks, Steelcase, Glu Mobile Jun 26 2014
VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing... Jan 21 2014
Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference Jan 08 2014
Auxilium Pharmaceuticals Presents Interim Data on XIAFLEX® for the Retreatment of Recurring... Jan 08 2014
Auxilium Pharmaceuticals, Inc. Submits Application To The FDA Requesting Approval Of XIAFLEX® For... Dec 20 2013
Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome... Dec 13 2013
Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX® for the Treatment of... Dec 06 2013
Auxilium Pharmaceuticals, Inc. To Present At The Oppenheimer Conference Dec 05 2013
Auxilium Pharmaceuticals, Inc. to Present Data on XIAFLEX® at the Fall Scientific Meeting of the... Nov 20 2013
Auxilium Announces Results Of The XIAFLEX® In Dupuytren's MULTICORD Contracture Trial Nov 18 2013
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results Nov 06 2013
Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013 Oct 24 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK